Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036, Due to the Launch of Drug Classes Such as Anti-B7-H3 ADC, PROTAC Protein Degrader, NTD AR Inhibitor, Radionuclide Therapy, and Several Others | DelveInsight

The metastatic castration-resistant prostate cancer (mCRPC) market is projected to reach USD 8B in the 7MM in 2025, supported by rising advanced disease prevalence (7.7M prevalent prostate cancer cases in 2025) and expanding precision medicine use (HRR mutations, PSMA expression). Growth is further driven by late-stage pipeline activity including Pfizer’s mevrometostat + enzalutamide (Phase III, launch expected 2026) and multiple PSMA-targeted radioligand therapies (e.g., 177Lu-PSMA-I&T, 177Lu-PNT200, 177Lu-DOTA-rosopatamab). Recent clinical readouts/collaborations across 2025–2026 add momentum to an increasingly competitive treatment landscape, with the report citing blockbuster-like prior performance from PLUVICTO (USD 1.3B global sales in 2024).

Analysis

This is less a single-stock event than a framing device for where value migrates in prostate oncology. The economic pool grows, but the margin pool shifts toward companies that control patient finding, isotope logistics, and treatment sequencing rather than just owning another me-too drug. That makes LNTH and TLX more interesting than the headline drug names: if PSMA-PET becomes the default gatekeeper, diagnostics and theranostic platforms can monetize every treatment path, even if the winning drug changes.

The more important second-order effect is cannibalization of legacy oral standards. As biomarker-selected, radioligand-heavy regimens move earlier, the duration of benefit for older AR-pathway and PARP franchises may compress, which is a slower but real headwind for broad oncology cash-flow assumptions. The market may be overestimating how fast new combinations convert into share; reimbursement friction, isotope supply, and center-level workflow bottlenecks usually delay adoption by quarters, not weeks.

The cleanest catalyst is data, not the report itself: phase III readouts and payer decisions over the next 1-3 quarters will tell us whether this is a market expansion story or a sequencing shift. Falsifiers are straightforward: safety signals, inferior OS/PFS, or a reimbursement path that keeps radioligands confined to late-line use. In that case, the upside to the basket is mostly narrative, and the right reaction is to fade strength rather than chase it.

Key Decisions for Investors

• Prefer LNTH as a 6-18 month structural winner on PSMA-PET adoption; buy on weakness, as the risk/reward is better than single-drug names because it monetizes the entire workflow rather than one trial outcome.
• Keep TLX on a watch-to-buy list into any pullback ahead of clinical/regulatory catalysts; the setup is asymmetric if radioligand utilization broadens, but downside is meaningful if reimbursement or manufacturing slows uptake.
• Do not pre-emptively chase PFE; use call spreads only after H2-2025 readouts if efficacy and tolerability are clean. Before then, the market is likely to overpay for optionality that is not yet de-risked.
• Avoid adding to ARVN on strength until there is proof that pure AR-degrader economics can coexist with earlier PSMA/radioligand use; the setup is vulnerable to share erosion even if the pipeline remains scientifically credible.
• Set an event alert on reimbursement and launch uptake for PSMA-linked therapies; if physician adoption is slower than consensus, fade the whole mCRPC innovation basket rather than owning the concept outright.